Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
| Title: | Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study |
|---|---|
| Authors: | Douma, Li-Anne H a; van der Noort, Vincent b; Lalezari, Ferry c; de Vries, Jeltje F b; Monkhorst, Kim d; Smesseim, Illaa e; Baas, Paul e; Schilder, Bodien e; Vermeulen, Marrit b; Burgers, Jacobus A e, *; de Gooijer, Cornedine J e |
| Source: | In The Lancet Oncology December 2025 26(12):1676-1684 |
| Database: | ScienceDirect |